Liquid Biopsy Market (4th Edition), 2018-2022 (Historical Trends) and 2023-2035 (Forecasted Estimates): Distribution by Application (Early Cancer Diagnosis, Patient Monitoring, Treatment Selection, Recurrence Monitoring and Others), Target Disease Indication (Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Prostate Cancer and Others), Type of Circulating Biomarker (Cell Free DNA, Cell Free RNA, Circulating Tumor DNA, Extracellular Vesicles and Others Circulating Biomarkers), Type of Sample (Blood / Plasma and Others), End users (Hospitals, Research Institutes and Others), Stage of Development (Launched and Under Development), Type of Product (Assay kits, Devices, Software/ Algorithms and others), Type of Technique (Polymerase Chain Reaction, Next Generation Sequencing and Others), Application Area ( Clinical use, Research use only) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
The global liquid biopsy market is expected to reach USD 5.4 billion in 2023 anticipated to grow at a CAGR of 15.2% during the forecast period 2023-2035.
Cancer remains a significant global health challenge, ranking as the second leading cause of death worldwide. By 2040, the World Health Organization (WHO) projects a staggering 16.3 million cancer-related deaths. Among all cancer types, breast cancer holds the highest occurrence globally, followed by lung, colorectal, and prostate cancers. Statistics from the Surveillance, Epidemiology, and End Results (SEER) program predict an 18% lifetime diagnosis rate for women with breast cancer, expecting around 297,790 new cases in 2023. To address this growing burden, various cancer research institutions actively pursue innovative methods and patient-focused approaches for early detection and treatment. Detecting cancer early is crucial for improving treatment effectiveness and increasing survival rates. While tissue biopsy has been the gold standard for diagnosis, its invasive nature—leading to discomfort, pain, and potential complications—has limited its widespread use. However, recent advancements in liquid biopsy have positioned it as a promising diagnostic technique for cancer. Over the past decade, liquid biopsy platforms have made significant progress, gaining regulatory approvals for minimally invasive blood-based tests. These tests enable early cancer detection and patient monitoring, offering accessibility and minimal invasiveness. By analyzing blood samples or other bodily fluids like urine or plasma, these tests identify genetic mutations and various circulating biomarkers, such as circulating tumor DNA, cell-free DNA, and extracellular vesicles. These non-invasive assessments are transforming cancer care, particularly for individuals in advanced cancer stages.
Report Coverage
Cancer remains a significant global health challenge, ranking as the second leading cause of death worldwide. By 2040, the World Health Organization (WHO) projects a staggering 16.3 million cancer-related deaths. Among all cancer types, breast cancer holds the highest occurrence globally, followed by lung, colorectal, and prostate cancers. Statistics from the Surveillance, Epidemiology, and End Results (SEER) program predict an 18% lifetime diagnosis rate for women with breast cancer, expecting around 297,790 new cases in 2023. To address this growing burden, various cancer research institutions actively pursue innovative methods and patient-focused approaches for early detection and treatment. Detecting cancer early is crucial for improving treatment effectiveness and increasing survival rates. While tissue biopsy has been the gold standard for diagnosis, its invasive nature—leading to discomfort, pain, and potential complications—has limited its widespread use. However, recent advancements in liquid biopsy have positioned it as a promising diagnostic technique for cancer. Over the past decade, liquid biopsy platforms have made significant progress, gaining regulatory approvals for minimally invasive blood-based tests. These tests enable early cancer detection and patient monitoring, offering accessibility and minimal invasiveness. By analyzing blood samples or other bodily fluids like urine or plasma, these tests identify genetic mutations and various circulating biomarkers, such as circulating tumor DNA, cell-free DNA, and extracellular vesicles. These non-invasive assessments are transforming cancer care, particularly for individuals in advanced cancer stages.
Report Coverage
- The report extensively examines the liquid biopsy market across various parameters including application, target disease indication, type of circulating biomarker, type of sample, end users, stage of development, type of product, type of technique, application area and key geographical regions
- It analyzes the market growth drivers, restraints, opportunities, and challenges, evaluating their impact on the industry.
- The report assesses both advantages and obstacles within the market, providing insights into the competitive landscape for leading market players.
- Forecasting revenue for market segments in relation to four major regions is a key component of this report
- It offers a detailed outline of the research methodology used to study liquid biopsy and non-invasive cancer diagnostics, highlighting methodologies, assumptions, and quality control measures ensuring reliability and accuracy.
- Historical trends, currency fluctuations, foreign exchange impacts, economic recessions, and inflation measurements that influence the liquid biopsy market are thoroughly examined.
- Summarizing key insights from the research, the report provides a high-level view of the current status of the liquid biopsy market and its anticipated evolution in short, mid, and long terms.
- An overview of cancer statistics underscores the global disease burden, the importance of early cancer detection and screening, and explores different types of circulating biomarkers based on functionality. It also delves into emerging trends in intellectual property related to non-invasive cancer diagnostics, liquid biopsy costs, benefits, challenges, and their significance.
- The report emphasizes the necessity and significance of non-invasive cancer diagnostics, encompassing various imaging techniques, screening assays, and advanced diagnostic approaches along with their respective advantages and disadvantages.
- A detailed assessment of the liquid biopsy product market is provided based on multiple parameters such as development stage, product types (assay kits, devices, software/algorithms), sample types, techniques used, circulating biomarkers, target disease indications, applications, and key market players.
- Detailed profiles of leading liquid biopsy companies are presented, focusing on their establishment, workforce, headquarters, financial performance, product portfolio, recent developments, and future outlook.
- The report examines recent collaborations within the liquid biopsy market, considering parameters like partnership types, circulating biomarkers, target disease indications, most active players, and regional distributions.
- An in-depth analysis of funding and investments in liquid biopsy companies between 2016 and 2023 is provided, considering various parameters like funding types, target disease indications, application areas, geographic distribution, leading investors, and notable funding instances.
- A comprehensive evaluation of liquid biopsy product competitiveness is conducted based on supplier strength, product attributes, company size, and technological advancements.
- Initiatives by major pharmaceutical companies are thoroughly reviewed, focusing on areas of interest, stages of development, product types, target indications, and application areas.
- Historical acquisition activities since 2016 are examined, identifying potential acquisition targets within the industry.
- The report offers detailed insight into various non-invasive diagnostic tests, beyond liquid biopsies, offered by different companies for cancer screening and early detection.
- An in-depth examination of growth factors, potential limitations, emerging opportunities, and existing challenges influencing the liquid biopsy market is conducted.
- Amoy Diagnostics
- ArcherDX
- Biocartis
- Cell Search
- CellMax Life
- Datar Cancer Genetics
- DiaCarta, EONE-DIAGNOMICS
- Exosome Diagnostics
- GeneCast Biotechnology
- Integrated DNA Technologies
- Lucence
- MDNA Life Sciences
- Miltenyi Biotec
- NeoGenomics
- ONCODE Scientific
- OncoDNA
- QIAGEN
- PANAGENE
- Personal Genome Diagnostics
- Predicin
- ScreenCell
- Tecan
- Thermo Fisher Scientific
1. PREFACE
1.1. Chapter Overview
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Cancer Statistics and Burden of the Disease
5.3. Importance of Early Cancer Detection
5.4. Cancer Screening and Diagnosis
5.5 Conventional Invasive Cancer Diagnostic Tests
5.5.1. Biopsy
5.5.2. Fine Needle Aspiration Biopsy
5.5.3. Core Needle Aspiration Biopsy
5.5.4. Vacuum-Assisted Biopsy
5.5.5. Image Guided Biopsy
5.5.6. Sentinel Node Biopsy
5.5.7. Surgical Biopsy
5.5.8. Endoscopic Biopsy
5.5.9. Bone Marrow Biopsy
5.5.10. Endoscopy
5.6. Need for Non-Invasive Approaches
5.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
5.7.1 Circulating Tumor Cells
5.7.2. Circulating Tumor DNA/ Cell Free DNA
5.7.3. Exosomes
5.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
5.9. Latest Intellectual Property Trends in Non-Invasive Cancer Diagnostics
5.10. Challenges Associated with Non-Invasive Cancer Diagnostics
5.11. Future Perspectives
6. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS
6.1. Chapter Overview
6.2. Diagnostic Imaging
6.2.1. Magnetic Resonance Imaging (MRI)
6.2.2. Mammography
6.2.3. Bone Scan
6.2.4. Computerized Tomography (CT) Scan
6.2.5. Integrated Positron Emission Tomography (PET)- CT Scan
6.2.6. Ultrasound
6.2.7. X-ray Radiography (Barium Enema)
6.3. Screening Assays
6.3.1. Circulating Tumor Marker Test
6.3.2. Digital Rectal Exam (DRE)
6.3.3. Fecal Occult Blood Test (FOBT)
6.3.4. Multigated Acquisition (MUGA) Scan
6.3.5. Papanicolaou Test and Human Papilloma Virus Test
6.4. Advanced Non-Invasive Approaches
6.4.1. Cytogenetic / Gene Expression Studies
6.4.2. Molecular Signature-based Non-Invasive Methods
6.4.3. Saliva-based Oral Cancer Diagnostics
6.4.4. Vital Staining
6.4.5. Optical Biopsy
6.4.6 Other Diagnostic Techniques
7. LIQUID BIOPSY: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Liquid Biopsy Products: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Type of Sample
7.2.4. Analysis by Type of Technique
7.2.5. Analysis by Type of Circulating Biomarker
7.2.6. Analysis by Tumor
7.2.7. Analysis by Target Disease Indication
7.2.8. Analysis by Application
7.2.9. Analysis by Application Area
7.3. Liquid Biopsy Product Manufacturers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters (Region)
7.3.3. Analysis by Location of Headquarters (Country)
7.3.4. Most Active Players: Analysis by Number of Liquid Biopsy Products
7.4. Liquid Biopsy Products: Other Liquid Biopsy Products, Kits and Consumables
7.5. Liquid Biopsy Products: Contract Service Providers
8. COMPANY PROFILES
8.1. Chapter Overview
8.2.1. Amoy Diagnostics
8.2.1.1. Company Overview
8.2.1.2. Product Portfolio
8.2.1.3. Recent Developments and Future Outlook
8.2.2. ArcherDX
8.2.2.1. Company Overview
8.2.2.2 Product Portfolio
8.2.2.3. Recent Developments and Future Outlook
8.2.3. DiaCarta
8.2.3.1. Company Overview
8.2.3.2. Product Portfolio
8.2.3.3 Recent Developments and Future Outlook
8.2.4. Integrated DNA Technologies
8.2.4.1. Company Overview
8.2.4.2. Product Portfolio
8.2.4.3. Recent Developments and Future Outlook
8.2.5 MDNA Life Sciences
8.2.5.1. Company Overview
8.2.5.2. Financial Information
8.2.5.3 Product Portfolio
8.2.5.4. Recent Developments and Future Outlook
8.2.6. NeoGenomics
8.2.6.1. Company Overview
8.2.6.2. Product Portfolio
8.2.6.3. Recent Developments and Future Outlook
8.2.7. ONCODE Scientific
8.2.7.1. Company Overview
8.2.7.2. Product Portfolio
8.2.7.3. Recent Developments and Future Outlook
8.2.8. QIAGEN
8.2.8.1. Company Overview
8.2.8.2. Financial Information
8.2.8.3. Product Portfolio
8.2.8.4. Recent Developments and Future Outlook
8.2.9. ScreenCell
8.2.9.1. Company Overview
8.2.9.2. Financial Information
8.2.9.3. Product Portfolio
8.2.9.4. Recent Developments and Future Outlook
8.2.10. Thermo Fisher Scientific
8.2.10.1. Company Overview
8.2.10.2. Financial Information
8.2.10.3. Product Portfolio
8.2.10.4. Recent Developments and Future Outlook
8.3. Other Leading Players in Liquid Biopsy Market
8.3.1. Biocartis
8.3.1.1. Company Overview
8.3.1.2. Product Portfolio
8.3.2. Cell Search
8.3.2.1. Company Overview
8.3.2.2. Product Portfolio
8.3.3. CellMax Life
8.3.3.1. Company Overview
8.3.3.2. Product Portfolio
8.3.4. Datar Cancer Genetics
8.3.4.1. Company Overview
8.3.4.2. Product Portfolio
8.3.5. EONE-DIAGNOMICS Genome Center
8.3.5.1. Company Overview
8.3.5.2. Product Portfolio
8.3.6. Exosome Diagnostics
8.3.6.1. Company Overview
8.3.6.2. Product Portfolio
8.3.7. GeneCast Biotechnology
8.3.7.1. Company Overview
8.3.7.2. Product Portfolio
8.3.8. Inivata
8.3.8.1. Company Overview
8.3.8.2. Product Portfolio
8.3.9. Lucence
8.3.90.1. Company Overview
8.3.9.2. Product Portfolio
8.3.10. Miltenyi Biotec
8.3.10.1. Company Overview
8.3.10.2. Product Portfolio
8.3.11. OncoDNA
8.3.11.1. Company Overview
8.3.11.2. Product Portfolio
8.3.12. PANAGENE
8.3.12.1. Company Overview
8.3.12.2. Product Portfolio
8.3.13. Personal Genome Diagnostics
8.3.13.1. Company Overview
8.3.13.2. Product Portfolio
8.3.14. Predicine
8.3.14.1. Company Overview
8.3.14.2. Product Portfolio
8.3.15. Tecan
8.3.15.1. Company Overview
8.3.15.2. Product Portfolio
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Liquid Biopsy: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Year of Partnership and Type of Partner
9.3.6. Analysis by Type of Partnership and Type of Partner
9.3.7. Analysis by Type of Circulating Biomarker
9.3.8. Analysis by Target Disease Indication
9.3.9. Most Active Players: Analysis by Number of Partnerships
9.3.10. Analysis by Geography
9.3.10.1. Local and International Agreements
9.3.10.2 Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Liquid Biopsy: Funding and Investment Analysis
10.3.1. Analysis by Year of Investment
10.3.2. Analysis of Amount Invested by Year
10.3.3. Analysis by Type of Funding
10.3.4. Analysis of Amount Invested by Type of Funding
10.3.5. Analysis by Year and Type of Funding
10.3.6. Analysis by Type of Circulating Biomarker
10.3.7. Analysis by Target Disease Indication
10.3.8. Analysis by Application Area
10.3.9. Analysis by Geography
10.3.10. Most Active Players: Analysis by Number of Funding Instances
10.3.11. Most Active Players: Analysis by Amount Raised
10.3.12. Most Active Investors: Analysis by Number of Funding Instances
11. PRODUCT COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.3. Assumptions and Key Parameters
11.4. Liquid Biopsy: Product Competitiveness Analysis
11.4.1. Liquid Biopsy Assay Kits
11.4.1.1. Products Offered by Players based in North America
11.4.1.2. Products Offered by Players based in Europe
11.4.1.3. Products Offered by Players based in Asia-Pacific
11.4.1.4. Products Offered by Players based in Rest of the World
11.4.2. Liquid Biopsy Devices
11.4.2.1. Products Offered by Players based in North America
11.4.2.2. Products Offered by Players based in Europe and Asia-Pacific
11.4.3. Liquid Biopsy Software
12. BIG PHARMA INITIATIVES
12.1. Chapter Overview
12.2. Top Pharmaceutical Companies
12.2.1. Analysis by Type of Initiative
12.2.2. Analysis by Stage of Development
12.2.3. Analysis by Type of Product
12.2.4. Analysis by Type of Circulating Biomarker
12.2.5. Analysis by Target Disease Indication
12.2.6. Analysis by Application
12.2.7. Analysis by Application Area
13. KEY ACQUISITION TARGETS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Scoring Criteria and Key Assumptions
13.4. Potential Acquisition Targets in North America
13.5. Potential Acquisition Targets in Europe
13.6. Potential Acquisition Targets in Asia-Pacific and Rest of the World
13.7. Concluding Remarks
14. OTHER NON-INVASIVE CANCER DIAGNOSTICS
14.1. Chapter Overview
14.2. Non-Blood-based Biomarker Detection Tests
14.3. FOBT and Fecal Immunochemical Tests (FIT)
14.4. Pigmented Lesion Assays
14.5. Stool DNA (sDNA)-based Tests
14.6. Volatile Organic Compound (VOC) Detection Tests
14.7. Other Non-Invasive Cancer Diagnostics: Market Landscape
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion
16. GLOBAL LIQUID BIOPSY MARKET
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Global Non-Invasive Cancer Diagnostics Market, (2023-2035)
16.4. Global Liquid Biopsy Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.4.1. Scenario Analysis
16.5. Key Market Segmentations
16.6. Dynamic Dashboard
17. LIQUID BIOPSY MARKET, BY APPLICATION
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Early Cancer Diagnosis: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.4. Patient Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.5. Recurrence Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.6. Data Triangulation and Validation
18. LIQUID BIOPSY MARKET, BY TARGET DISEASE INDICATION
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Bladder Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.4. Neurological Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.5. Breast Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.6. Cervical Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.7. Head and Neck Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.8. Leukemia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.9. Liver Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.10. Lung Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.11. Melanoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.12. Nasopharyngeal Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.13. Oesophagus Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.14. Ovarian Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.15. Pancreatic Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.16. Prostate Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.17. Sarcoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.18. Stomach Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.19. Thyroid Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.20. Data Triangulation and Validation
19. LIQUID BIOPSY MARKET, BY TYPE OF CIRCULATING BIOMARKER
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Cell-Free DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.4. Circulating Tumor DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.5. Extracellular Vesicles: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.6. Other Circulating Biomarkers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation
20. LIQUID BIOPSY MARKET, BY TYPE OF SAMPLE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Blood / Plasma Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.4. Other Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.5. Data Triangulation and Validation
21. LIQUID BIOPSY MARKET, BY TYPE OF END-USER
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Hospitals: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.4. Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.5. Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.6. Data Triangulation and Validation
22. LIQUID BIOPSY MARKET, BY KEY GEOGRAPHICAL REGIONS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.5. Asia-Pacific and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.6. Data Triangulation and Validation
23. SURVEY INSIGHTS
23.1. Chapter Overview
23.2. Company Specifics of Respondents
23.3. Analysis by Seniority Level of Respondents
23.4. Analysis by Type of Product Portfolio
23.5. Analysis by Type of Products / Services Offered
23.6. Analysis by Stage of Development of Product
23.7. Analysis by Application Area
23.8. Analysis by Likely Market Size
24. CONCLUSION
25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Foundation for the National Institutes of Health
25.2.1. Company Snapshot
25.2.2. Interview Transcript
25.3. Bahia Software
25.3.1. Company Snapshot
25.3.2. Interview Transcript
25.4. Genostics
25.4.1. Company Snapshot
25.4.2. Interview Transcript
25.5. Oncophenomics
25.5.1. Company Snapshot
25.5.2. Interview Transcript
25.6. Minomic International
25.6.1. Company Snapshot
25.6.2. Interview Transcript
25.7. IVDiagnostics
25.7.1. Company Snapshot
25.7.2. Interview Transcript
25.8. Tymora Analytical Operations
25.8.1. Company Snapshot
25.8.2. Interview Transcript
25.9. ProXeom
25.9.1. Company Snapshot
25.9.2. Interview Transcript
25.10. MiNDERA
25.10.1. Company Snapshot
25.10.2. Interview Transcript
25.11. Resolution Bioscience
25.11.1. Company Snapshot
25.11.2. Interview Transcript
25.12. Nanostics
25.12.1. Company Snapshot
25.12.2. Interview Transcript
25.13. DermTech
25.13.1. Company Snapshot
25.13.2. Interview Transcript
25.14. iCellate Medical
25.14.1. Company Snapshot
25.14.2. Interview Transcript
25.15. VolitionRx
25.15.1. Company Snapshot
25.15.2. Interview Transcript
25.16. OncoDNA
25.16.1. Company Snapshot
25.16.2. Interview Transcript
25.17. LCM Genect
25.17.1. Company Snapshot
25.17.2. Interview Transcript
25.18. Sienna Cancer Diagnostics
25.18.1. Company Snapshot
25.18.2. Interview Transcript
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Chapter Overview
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Cancer Statistics and Burden of the Disease
5.3. Importance of Early Cancer Detection
5.4. Cancer Screening and Diagnosis
5.5 Conventional Invasive Cancer Diagnostic Tests
5.5.1. Biopsy
5.5.2. Fine Needle Aspiration Biopsy
5.5.3. Core Needle Aspiration Biopsy
5.5.4. Vacuum-Assisted Biopsy
5.5.5. Image Guided Biopsy
5.5.6. Sentinel Node Biopsy
5.5.7. Surgical Biopsy
5.5.8. Endoscopic Biopsy
5.5.9. Bone Marrow Biopsy
5.5.10. Endoscopy
5.6. Need for Non-Invasive Approaches
5.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
5.7.1 Circulating Tumor Cells
5.7.2. Circulating Tumor DNA/ Cell Free DNA
5.7.3. Exosomes
5.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
5.9. Latest Intellectual Property Trends in Non-Invasive Cancer Diagnostics
5.10. Challenges Associated with Non-Invasive Cancer Diagnostics
5.11. Future Perspectives
6. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS
6.1. Chapter Overview
6.2. Diagnostic Imaging
6.2.1. Magnetic Resonance Imaging (MRI)
6.2.2. Mammography
6.2.3. Bone Scan
6.2.4. Computerized Tomography (CT) Scan
6.2.5. Integrated Positron Emission Tomography (PET)- CT Scan
6.2.6. Ultrasound
6.2.7. X-ray Radiography (Barium Enema)
6.3. Screening Assays
6.3.1. Circulating Tumor Marker Test
6.3.2. Digital Rectal Exam (DRE)
6.3.3. Fecal Occult Blood Test (FOBT)
6.3.4. Multigated Acquisition (MUGA) Scan
6.3.5. Papanicolaou Test and Human Papilloma Virus Test
6.4. Advanced Non-Invasive Approaches
6.4.1. Cytogenetic / Gene Expression Studies
6.4.2. Molecular Signature-based Non-Invasive Methods
6.4.3. Saliva-based Oral Cancer Diagnostics
6.4.4. Vital Staining
6.4.5. Optical Biopsy
6.4.6 Other Diagnostic Techniques
7. LIQUID BIOPSY: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Liquid Biopsy Products: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Type of Sample
7.2.4. Analysis by Type of Technique
7.2.5. Analysis by Type of Circulating Biomarker
7.2.6. Analysis by Tumor
7.2.7. Analysis by Target Disease Indication
7.2.8. Analysis by Application
7.2.9. Analysis by Application Area
7.3. Liquid Biopsy Product Manufacturers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters (Region)
7.3.3. Analysis by Location of Headquarters (Country)
7.3.4. Most Active Players: Analysis by Number of Liquid Biopsy Products
7.4. Liquid Biopsy Products: Other Liquid Biopsy Products, Kits and Consumables
7.5. Liquid Biopsy Products: Contract Service Providers
8. COMPANY PROFILES
8.1. Chapter Overview
8.2.1. Amoy Diagnostics
8.2.1.1. Company Overview
8.2.1.2. Product Portfolio
8.2.1.3. Recent Developments and Future Outlook
8.2.2. ArcherDX
8.2.2.1. Company Overview
8.2.2.2 Product Portfolio
8.2.2.3. Recent Developments and Future Outlook
8.2.3. DiaCarta
8.2.3.1. Company Overview
8.2.3.2. Product Portfolio
8.2.3.3 Recent Developments and Future Outlook
8.2.4. Integrated DNA Technologies
8.2.4.1. Company Overview
8.2.4.2. Product Portfolio
8.2.4.3. Recent Developments and Future Outlook
8.2.5 MDNA Life Sciences
8.2.5.1. Company Overview
8.2.5.2. Financial Information
8.2.5.3 Product Portfolio
8.2.5.4. Recent Developments and Future Outlook
8.2.6. NeoGenomics
8.2.6.1. Company Overview
8.2.6.2. Product Portfolio
8.2.6.3. Recent Developments and Future Outlook
8.2.7. ONCODE Scientific
8.2.7.1. Company Overview
8.2.7.2. Product Portfolio
8.2.7.3. Recent Developments and Future Outlook
8.2.8. QIAGEN
8.2.8.1. Company Overview
8.2.8.2. Financial Information
8.2.8.3. Product Portfolio
8.2.8.4. Recent Developments and Future Outlook
8.2.9. ScreenCell
8.2.9.1. Company Overview
8.2.9.2. Financial Information
8.2.9.3. Product Portfolio
8.2.9.4. Recent Developments and Future Outlook
8.2.10. Thermo Fisher Scientific
8.2.10.1. Company Overview
8.2.10.2. Financial Information
8.2.10.3. Product Portfolio
8.2.10.4. Recent Developments and Future Outlook
8.3. Other Leading Players in Liquid Biopsy Market
8.3.1. Biocartis
8.3.1.1. Company Overview
8.3.1.2. Product Portfolio
8.3.2. Cell Search
8.3.2.1. Company Overview
8.3.2.2. Product Portfolio
8.3.3. CellMax Life
8.3.3.1. Company Overview
8.3.3.2. Product Portfolio
8.3.4. Datar Cancer Genetics
8.3.4.1. Company Overview
8.3.4.2. Product Portfolio
8.3.5. EONE-DIAGNOMICS Genome Center
8.3.5.1. Company Overview
8.3.5.2. Product Portfolio
8.3.6. Exosome Diagnostics
8.3.6.1. Company Overview
8.3.6.2. Product Portfolio
8.3.7. GeneCast Biotechnology
8.3.7.1. Company Overview
8.3.7.2. Product Portfolio
8.3.8. Inivata
8.3.8.1. Company Overview
8.3.8.2. Product Portfolio
8.3.9. Lucence
8.3.90.1. Company Overview
8.3.9.2. Product Portfolio
8.3.10. Miltenyi Biotec
8.3.10.1. Company Overview
8.3.10.2. Product Portfolio
8.3.11. OncoDNA
8.3.11.1. Company Overview
8.3.11.2. Product Portfolio
8.3.12. PANAGENE
8.3.12.1. Company Overview
8.3.12.2. Product Portfolio
8.3.13. Personal Genome Diagnostics
8.3.13.1. Company Overview
8.3.13.2. Product Portfolio
8.3.14. Predicine
8.3.14.1. Company Overview
8.3.14.2. Product Portfolio
8.3.15. Tecan
8.3.15.1. Company Overview
8.3.15.2. Product Portfolio
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Liquid Biopsy: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Year of Partnership and Type of Partner
9.3.6. Analysis by Type of Partnership and Type of Partner
9.3.7. Analysis by Type of Circulating Biomarker
9.3.8. Analysis by Target Disease Indication
9.3.9. Most Active Players: Analysis by Number of Partnerships
9.3.10. Analysis by Geography
9.3.10.1. Local and International Agreements
9.3.10.2 Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Liquid Biopsy: Funding and Investment Analysis
10.3.1. Analysis by Year of Investment
10.3.2. Analysis of Amount Invested by Year
10.3.3. Analysis by Type of Funding
10.3.4. Analysis of Amount Invested by Type of Funding
10.3.5. Analysis by Year and Type of Funding
10.3.6. Analysis by Type of Circulating Biomarker
10.3.7. Analysis by Target Disease Indication
10.3.8. Analysis by Application Area
10.3.9. Analysis by Geography
10.3.10. Most Active Players: Analysis by Number of Funding Instances
10.3.11. Most Active Players: Analysis by Amount Raised
10.3.12. Most Active Investors: Analysis by Number of Funding Instances
11. PRODUCT COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.3. Assumptions and Key Parameters
11.4. Liquid Biopsy: Product Competitiveness Analysis
11.4.1. Liquid Biopsy Assay Kits
11.4.1.1. Products Offered by Players based in North America
11.4.1.2. Products Offered by Players based in Europe
11.4.1.3. Products Offered by Players based in Asia-Pacific
11.4.1.4. Products Offered by Players based in Rest of the World
11.4.2. Liquid Biopsy Devices
11.4.2.1. Products Offered by Players based in North America
11.4.2.2. Products Offered by Players based in Europe and Asia-Pacific
11.4.3. Liquid Biopsy Software
12. BIG PHARMA INITIATIVES
12.1. Chapter Overview
12.2. Top Pharmaceutical Companies
12.2.1. Analysis by Type of Initiative
12.2.2. Analysis by Stage of Development
12.2.3. Analysis by Type of Product
12.2.4. Analysis by Type of Circulating Biomarker
12.2.5. Analysis by Target Disease Indication
12.2.6. Analysis by Application
12.2.7. Analysis by Application Area
13. KEY ACQUISITION TARGETS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Scoring Criteria and Key Assumptions
13.4. Potential Acquisition Targets in North America
13.5. Potential Acquisition Targets in Europe
13.6. Potential Acquisition Targets in Asia-Pacific and Rest of the World
13.7. Concluding Remarks
14. OTHER NON-INVASIVE CANCER DIAGNOSTICS
14.1. Chapter Overview
14.2. Non-Blood-based Biomarker Detection Tests
14.3. FOBT and Fecal Immunochemical Tests (FIT)
14.4. Pigmented Lesion Assays
14.5. Stool DNA (sDNA)-based Tests
14.6. Volatile Organic Compound (VOC) Detection Tests
14.7. Other Non-Invasive Cancer Diagnostics: Market Landscape
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion
16. GLOBAL LIQUID BIOPSY MARKET
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Global Non-Invasive Cancer Diagnostics Market, (2023-2035)
16.4. Global Liquid Biopsy Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.4.1. Scenario Analysis
16.5. Key Market Segmentations
16.6. Dynamic Dashboard
17. LIQUID BIOPSY MARKET, BY APPLICATION
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Early Cancer Diagnosis: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.4. Patient Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.5. Recurrence Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.6. Data Triangulation and Validation
18. LIQUID BIOPSY MARKET, BY TARGET DISEASE INDICATION
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Bladder Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.4. Neurological Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.5. Breast Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.6. Cervical Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.7. Head and Neck Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.8. Leukemia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.9. Liver Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.10. Lung Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.11. Melanoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.12. Nasopharyngeal Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.13. Oesophagus Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.14. Ovarian Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.15. Pancreatic Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.16. Prostate Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.17. Sarcoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.18. Stomach Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.19. Thyroid Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.20. Data Triangulation and Validation
19. LIQUID BIOPSY MARKET, BY TYPE OF CIRCULATING BIOMARKER
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Cell-Free DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.4. Circulating Tumor DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.5. Extracellular Vesicles: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.6. Other Circulating Biomarkers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation
20. LIQUID BIOPSY MARKET, BY TYPE OF SAMPLE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Blood / Plasma Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.4. Other Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.5. Data Triangulation and Validation
21. LIQUID BIOPSY MARKET, BY TYPE OF END-USER
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Hospitals: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.4. Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.5. Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.6. Data Triangulation and Validation
22. LIQUID BIOPSY MARKET, BY KEY GEOGRAPHICAL REGIONS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.5. Asia-Pacific and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.6. Data Triangulation and Validation
23. SURVEY INSIGHTS
23.1. Chapter Overview
23.2. Company Specifics of Respondents
23.3. Analysis by Seniority Level of Respondents
23.4. Analysis by Type of Product Portfolio
23.5. Analysis by Type of Products / Services Offered
23.6. Analysis by Stage of Development of Product
23.7. Analysis by Application Area
23.8. Analysis by Likely Market Size
24. CONCLUSION
25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Foundation for the National Institutes of Health
25.2.1. Company Snapshot
25.2.2. Interview Transcript
25.3. Bahia Software
25.3.1. Company Snapshot
25.3.2. Interview Transcript
25.4. Genostics
25.4.1. Company Snapshot
25.4.2. Interview Transcript
25.5. Oncophenomics
25.5.1. Company Snapshot
25.5.2. Interview Transcript
25.6. Minomic International
25.6.1. Company Snapshot
25.6.2. Interview Transcript
25.7. IVDiagnostics
25.7.1. Company Snapshot
25.7.2. Interview Transcript
25.8. Tymora Analytical Operations
25.8.1. Company Snapshot
25.8.2. Interview Transcript
25.9. ProXeom
25.9.1. Company Snapshot
25.9.2. Interview Transcript
25.10. MiNDERA
25.10.1. Company Snapshot
25.10.2. Interview Transcript
25.11. Resolution Bioscience
25.11.1. Company Snapshot
25.11.2. Interview Transcript
25.12. Nanostics
25.12.1. Company Snapshot
25.12.2. Interview Transcript
25.13. DermTech
25.13.1. Company Snapshot
25.13.2. Interview Transcript
25.14. iCellate Medical
25.14.1. Company Snapshot
25.14.2. Interview Transcript
25.15. VolitionRx
25.15.1. Company Snapshot
25.15.2. Interview Transcript
25.16. OncoDNA
25.16.1. Company Snapshot
25.16.2. Interview Transcript
25.17. LCM Genect
25.17.1. Company Snapshot
25.17.2. Interview Transcript
25.18. Sienna Cancer Diagnostics
25.18.1. Company Snapshot
25.18.2. Interview Transcript
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
